NAFLD/NASH

Determine levels of fibrosis and necroinflammatory activity

FibroTest-ActiTest can be used as a first-line screen to assess the condition of the liver using two diagnostic scores — one for liver fibrosis and one for liver inflammation — based on component tests for six biomarkers.

Advantages of FibroTest-ActiTest

  • The most reliable biomarker test, applicable to the largest number of patients (98%)
  • Offers the best performance of any test, at all stages of fibrosis, from a healthy liver to cirrhosis
  • The noninvasive test that is least affected by known risk factors for false positives and false negatives
  • Easy-to-read report shows both proprietary FibroTest and ActiTest scores and METAVIR fibrosis stage and activity grade

Key testing

FIBRO | FibroTest-ActiTest, Serum

A Test in Focus

Nikola Baumann, Ph.D., gives an overview of the new NASH-FibroTest available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

Learn more

Confidently evaluate for NASH, steatosis, and fibrosis/cirrhosis with one standard blood sample

In the United States, 80 to 100 million people are living with NAFLD. More than 25% of these patients will go on to develop NASH. Using a simple blood sample, this test combines 10 standard biomarkers into five scores to provide a complete assessment of the liver condition and the five main causes of liver disease, including hepatic steatosis, NASH, alcoholic steatohepatitis, fibrosis, and liver inflammation.

NSFIB | Nonalcoholic Steatohepatitis (NASH)-FibroTest, Serum and Plasma

By the numbers

80-100 million

number of Americans
who currently have NAFLD

25%

of NAFLD patients will progress to NASH

11%

of NASH patients will progress to cirrhosis

Learn more about how to order these evaluations at your institution.